Pacific Biosciences Announces Ten-Unit Sequel System Order for Annoroad
March 27 2018 - 7:30AM
Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leader
in long-read, high-resolution sequencing, today announced a
purchase order for 10 PacBio® Sequel® Systems that are expected to
be installed at Annoroad’s designated facility within the next
several months, enhancing Annoroad’s large-scale genomic service
capabilities across various fields within the life sciences such as
agriculture, basic research, medicine, and health.
The Sequel System, based on Pacific Biosciences’ unique Single
Molecule, Real-Time (SMRT®) technology, provides an unmatched depth
of genetic information through exceptionally long sequencing reads,
uniform coverage, and the highest consensus accuracy available
today. The technology allows scientists to go beyond fragmented
draft genomes and generate the most comprehensive de novo
assemblies.
“SMRT Sequencing has demonstrated great value in many
applications. The collaboration between Annoroad and PacBio
will further enhance Annoroad’s strategic maneuver and greatly
augment our competitiveness,” said Dawei Li, President of
Annoroad.
Dr. Michael Hunkapiller, Chairman and CEO of Pacific Biosciences
added: “We are excited that Annoroad, one of the leading service
providers in China, has decided to acquire the latest generation of
PacBio systems. By adopting our Sequel platform, Annoroad shows
confidence in integrating SMRT Sequencing into its wide array of
service offerings in which long reads based on SMRT technology have
become instrumental. We are confident that the Sequel Systems will
be an important contributor to many initiatives, such as the ATCG
(Annoroad Typical Chinese Genomes) Database announced in 2017 and
Annoroad’s ambition to become a bigger player on the world stage.
We are particularly pleased that Annoroad chose this significant
investment in our SMRT Sequencing technology even after careful
evaluation of alternatives.”
About Pacific BiosciencesPacific Biosciences of
California, Inc. (NASDAQ:PACB) offers sequencing systems to
help scientists resolve genetically complex problems. Based on its
novel Single Molecule, Real-Time (SMRT®) technology, Pacific
Biosciences’ products enable: de novo genome assembly to finish
genomes in order to more fully identify, annotate and decipher
genomic structures; full-length transcript analysis to improve
annotations in reference genomes, characterize alternatively
spliced isoforms in important gene families, and find novel genes;
targeted sequencing to more comprehensively characterize genetic
variations; and real-time kinetic information for epigenome
characterization. Pacific Biosciences’ technology provides high
accuracy, ultra-long reads, uniform coverage, and the ability to
simultaneously detect epigenetic changes. PacBio® sequencing
systems, including consumables and software, provide a simple,
fast, end-to-end workflow for SMRT Sequencing. More information is
available at www.pacb.com.
About AnnoroadAnnoroad is headquartered in
Beijing and is a well-known enterprise in the genomic industry in
China. The company is committed to providing cutting-edge genomic
solutions in both clinical testing and life science research.
Annoroad was given the distinction of “National High Innovative
Technology Enterprise,” and chartered as the national clinical
pilot site of NGS in China given its major position in the domestic
market and next-gen sequencing technology. Annoroad has
developed a series of NGS diagnostic applications in the field of
human reproduction, cancer, and rare diseases, forming an excellent
product line and brand recognition. In the field of science and
technology service, Annoroad provides state-of-the-art sequencing
and bioinformatics solutions for research organizations. More
information is available at http://en.annoroad.com/.
Forward-Looking StatementsAll statements in
this press release that are not historical are forward-looking
statements, including, among other things, statements relating to
purchase commitments, future installations, availability, uses,
quality or performance of, or benefits of using, products or
technologies, and other future events. You should not place undue
reliance on forward-looking statements because they involve known
and unknown risks, uncertainties, changes in circumstances and
other factors that are, in some cases, beyond Pacific Biosciences’
control and could cause actual results to differ materially from
the information expressed or implied by forward-looking statements
made in this press release. Factors that could materially affect
actual results can be found in Pacific Biosciences’ most recent
filings with the Securities and Exchange Commission, including
Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and
10-Q, and include those listed under the caption “Risk
Factors.”
Pacific Biosciences undertakes no obligation to revise or update
information in this press release to reflect events or
circumstances in the future, even if new information becomes
available.
Contacts
Media: Nicole Litchfield415.793.6468nicole@bioscribe.com
Investors:Trevin Rard650.521.8450ir@pacificbiosciences.com
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Apr 2023 to Apr 2024